查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439540

Apheresis - 全球市场考量、竞争格局、市场预测 (2030)

Apheresis - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

预计2022年全球单采市场规模将达到22.3066亿美元，到2030年将达到36.7155亿美元，在预测期内（2022-2028年）复合年增长率为8.75%。确实如此。 预计该市场将受到镰状细胞性贫血、血癌等血液疾病日益流行、各种生物製药公司对原料血浆的需求不断增加以及预测期内（2024-2030年）单采系统推出的推动。由于批准增加等因素，市场预计将繁荣。

单采市场动态

在单采市场的显着驱动因素中，血液疾病盛行率的增加是加速单采市场发展的主要因素。

例如，根据世界卫生组织 (WHO) (2023) 发布的数据，贫血是一个严重的全球公共卫生问题，影响幼儿和孕妇。 世界卫生组织的估计与最近的研究一致，该研究表明全世界约 42% 的 5 岁以下儿童和 40% 的孕妇被认为患有贫血。

此外，根据美国国家癌症研究所（NCI）（2022）的数据，预计2022年美国将新增约60,650名白血病患者。

根据 Global Blood Therapeutics（2020 年）的报告，2019 年欧洲有超过 52,000 人受到镰状细胞疾病的影响。 据同一消息来源称，与人口相比，该疾病使预期寿命减少约 25 至 30 年，并且往往主要影响非洲、地中海和南亚人后裔。

展望未来，预计血液疾病盛行率的增加将增加对单采设备的需求，并在 2022-2028 年研究期间推动单采设备的整体市场成长。

与单采市场相关的另一个主要驱动因素是用于管理和治疗各种疾病的创新单采设备的开发。

例如，2022 年 5 月，Baxter International Inc. 宣布在全球推出其下一代平台的最新版本 PrisMax 2。 PrisMax 2 专为治疗性血浆置换和其他器官支持护理而设计，为医院提供灵活性，以满足重症监护病房 (ICU) 的独特需求。

此外，2020 年4 月，Terumo BCT, Inc. 和Marker Therapeutics AG 将Terumo BCT 的Spectra Optia(TM) 单采血液成分系统与Marker Therapeutics 的D2000 吸附盒结合，治疗确诊患有COVID-19的18 岁患者。美国 FDA 宣布已授予治疗这些患者的紧急使用授权 (EUA)。

然而，与单采治疗相关的高成本和各种风险可能会限制单采市场的成长。

单采血液成分市场在 COVID-19 大流行期间呈现正面成长。 随着COVID-19患者数量的不断增加，血小板计数、纤维蛋白原、D-二聚体、凝血□原时间（PT）、活化部分凝血活□时间（APTT）等多种凝血参数已被发现为严重感染患者的併发症，因此血浆疗法已被赋予广泛的用途。 恢復期血浆疗法正在用于感染 COVID-19 的患者。 此外，根据《柳叶刀》杂誌发表的一篇文章，2020年5月28日至2022年6月15日期间，16,287名登记在册的恢復期患者中，有11,558名（71%）有资格接受恢復期血浆。 CP 疗法包括从刚从感染中恢復的患者身上收集血浆并将其註射到有危险的人体内。 因此，所有这些因素都对疫情期间全球单采市场的成长产生了积极影响。

随着大量人群接种疫苗以及包括医疗保健行业在内的各行业活动的恢復，单采血液成分市场预计在 2024-2030 年预测期内将进一步实现正增长。

本报告研究和分析了全球单采市场，提供市场规模和预测、驱动因素和挑战、公司和产品概况等。

目录

第1章单采市场报告简介

第2章单采市场执行摘要

  • 调查范围
  • 市场概览
  • 竞争评估

第3章监理分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第4章单采市场主要因素分析

  • 推动单采血液成分市场的因素
    • 血液疾病盛行率不断上升
    • 生药厂对原料血浆的需求不断增加
    • 与单采手术相关的优惠报销政策和资金
  • 单采市场的抑制因素与挑战
    • 与单采治疗相关的高成本
    • 与血浆分离术治疗相关的风险
  • 单采术市场机遇
    • 专为儿童设计的新型单采疗法的创新和研发激增
    • 降低脂蛋白分离术的成本，广泛提供治疗

第5章波特五力分析单采市场

第6章COVID-19对单采市场的影响分析

第7章 单采市场布局

  • 依产品类型
    • 单采机
    • 一次性物品
  • 按技术
    • 离心
    • 薄膜过滤
  • 透过治疗
    • 白血球去除手术
    • 血浆置换
    • 血小板交换
    • 红血球去除疗法
    • 其他
  • 依用途
    • 肾臟疾病
    • 血液疾病
    • 神经系统疾病
    • 自体免疫疾病
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他领域

第 8 章血浆分离术市场：全球公司份额分析 - 3 至 5 家主要公司

第9章单采市场公司与产品概况

  • Braun Melsungen AG
  • Asahi Kasei Corporation
  • Fresenius Kabi AG
  • Haemonetics Corporation
  • Terumo Corporation
  • Baxter International
  • Kaneka Corporation
  • Sumitomo Bakelite Company Limited
  • Medica SPA
  • Nikkiso Co., Ltd.
  • Cerus Corporation
  • Miltenyi Biotec B.V.& Co. KG
  • Haier Inc.
  • Otsuka Holdings

第10章KOL观看次数

第 11 章专案方法

第 12 章关于 DelveInsight

第 13 章免责声明与联络我们

Product Code: DIMDCL0364

Apheresis Market By Product Type (Apheresis Machine And Disposable), By Technology (Centrifugation And Membrane Filtration), By Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis And Others), By Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Automune Disorders, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to the rising increasing prevalence of hematological disorders and rise in the requirement of source plasma by various biopharmaceutical companies

The global apheresis market was valued at USD 2,230.66 million in 2022 and is estimated to grow at a CAGR of 8.75% during the forecast period (2022-2028) to reach USD 3,671.55 million by 2030. The apheresis market is slated to witness prosperity owing to factors such as the increasing prevalence of hematological disorders such as sickle cell anemia, blood cancers among others, the rise in the requirement of source plasma by various biopharmaceutical companies and an increase in the launch and approval of apheresis systems during the forecast period (2024-2030).

Apheresis Market Dynamics:

Among the noteworthy drivers of the apheresis market, the rising prevalence of hematological disorders turns out to be the major factor for accelerating the apheresis market.

For example, as per the data published by the World Health Organization (2023), anemia is a serious global public health problem that affects both young children and pregnant women. WHO estimates are in accordance with recent studies, and observes that about 42% of children less than 5 years of age and about 40% of the pregnant women are anemic globally.

Moreover, as per the National Cancer Institute 2022 (NCI), it has been estimated that there will be around 60,650 new cases of leukemia in the United States in 2022.

The report by Global Blood Therapeutics 2020 showed that sickle cell disease affected more than 52,000 people living in Europe in 2019. As per the same source, the condition carries a life expectancy of about 25 to 30 years below the general population and tends to predominantly affect the African, Mediterranean and the South Asian descent people.

Henceforth, the increasing prevalence of hematological disorders, will increase the demand for apheresis devices, which is anticipated to propel the overall market growth of the apheresis devices in the study period of 2022 - 2028.

Another major driver pertaining to the apheresis market is the development of innovative apheresis devices for the management and treatment of various diseases.

For example, in May 2022, Baxter International Inc., announced the global launch of PrisMax 2, the latest version of the company's next-generation platform. PrisMax 2 is designed for therapeutic plasma exchange therapy and other organ support therapies, while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU).

Furthermore, in April 2020, Terumo BCT, Inc. and Marker Therapeutics AG announced that the US FDA has issued Emergency Use Authorization for the use of Terumo BCT's Spectra Optia(TM) Apheresis System combined with Marker Therapeutics' D2000 Adsorption Cartridge to treat patients 18 years of age or older with confirmed COVID-19.

However, high costs and the various risks associated with apheresis treatment may act as restraining factors for the apheresis market growth.

The apheresis market reported a period of positive growth during the COVID-19 pandemic. Owing to rise in the COVID-19 cases, various coagulation parameters such as the platelet count, fibrinogen, D-dimmer, prothrombin time (PT), activated partial thromboplastin time (aPTT), were found as a complication among the patients that were severely infected, thus extensive applications pertaining to plasma therapies were given. The convalescent plasma therapy is used in patients that got infected due to COVID-19. Moreover, as per the article published in the Lancet Journal, between May 28, 2020 and June 15, 2022, 11558 (71%) of 16287 patients enrolled in recovery were eligible to receive convalescent plasma. CP therapy involves the collection of plasma from the patient's body who has recently recovered from infection and infusion of that collected plasma into the body of the individuals that are at a risk. Thus, all these factors had positively impacted the growth of the global apheresis market during the pandemic.

With large number of masses being vaccinated and with the resumption of activities across industries including the healthcare sector, the apheresis market is further expected to grow positively during the forecast period from 2024-2030.

Apheresis Market Segment Analysis:

Apheresis Market by Product Type (Apheresis machines and Disposables), Technology (Centrifugation and Membrane filtration), Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis, and Others), Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Autoimmune Disorders and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the product type segment of the apheresis market, the disposables category is projected to register a significant growth in revenue and was valued at USD 1,376.18 million in 2022 and will grow at a CAGR of 8.26% during the forecast period (2022-2028) to reach USD 2,204.25 million by 2030.

This can be can be attributed to the increased consumption of disposables in the process of apheresis. The disposables present in apheresis machines are manufactured and designed exclusively for one-time use, in order to ensure contamination-free transfer of blood components and maintain sterile conditions. Disposables form a key component for any apheresis system to deliver quality treatment, because of which all the key market players ensure a strong disposable kit profile for their apheresis systems. The Plasmat Futura Kit from B. Braun Melsungen AG, LIFE 21? and LIFE 18(TM) apheresis units disposables from Miltenyi Biotec, disposable TPE 2000 Set for PRISMAFLEX System from Baxter are some of the examples of quality disposables manufactured by key companies in order to build and flourish their market for apheresis.

In addition, recent developments by big market players in order to expand their expertise to more advanced disposable systems is further expected to boost the demand for disposables. For example, in January 2020, Fresenius Kabi AG inaugurated the expansion of the company's production site in Dominican Republic, having advanced production equipment, plasma kit assembly lines and sterilization units, enabling the company to meet the rising demand for high-quality disposables.

Hence, the interplay of all the aforementioned factors is anticipated to propel the market for disposables in the upcoming years.

North America is expected to dominate the overall Apheresis Market:

Among all the regions, North America is expected to lead in revenue generation in the global apheresis market and was valued at USD 979.12 million in 2022. It will grow at a CAGR of 8.44% during the forecast period from 2024 to 2030 to reach USD 1,584.64 million by 2030.

This domination is due to the rising prevalence of chronic diseases and cancers in the region. Moreover, the increase in the number of complex surgical procedures and the rising demand for blood components will also aid in the growth of apheresis market in the North America region.

According to the figures provided by American Cancer Society 2022, it is estimated that there will be nearly 60,650 news cases of leukemia in the year 2023 in the United States. As per the National Cancer Institute 2022, in the year 2019, there were an estimated 472,714 people living with leukemia in the United States. The above statics clearly indicates that the incidence of leukemia is surging every year.

White blood cell reduction apheresis is primarily used as a treatment for patients with leukemia whose blood white cell counts are excessively high. Thus, the increasing prevalence of leukemia in the United Sates will increase the demand of apheresis in the market.

The American Association for the Surgery of Trauma reports that in the United States, injury accounts for over 150,000 deaths and over 3 million non-fatal injuries per year. The injuries undergo some sort of surgical procedure for its treatment or management. Surgical procedure are usually accompanied with blood or blood components transfusion and the blood components can be separated and stored with the aid of apheresis. Therefore, the increasing number of injuries will shoot up the number of surgical procedures, thereby increasing the demand of blood component transfusion, henceforth propelling the demand for apheresis in the market.

Therefore, along with the presence of large number of geriatric patients prone to chronic disorders in North America and the increasing focus of manufacturers on launching new products in the market is expected to bolster the growth of the apheresis market in the overall North America region during the forecast period.

Apheresis Market Key Players:

Some of the key market players operating in the apheresis market include Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter International, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V & Co., KG, Haier Inc., Otsuka Holdings and others.

Recent Developmental Activities in Apheresis Market:

In June 2022, Terumo, a medical technology company, announces that the UK's NHS England has selected the Spectra OptiaR Apheresis System through the NHS MedTech Funding Mandate to treat sickle cell disease. As a result, Spectra Optia will be deployed more widely in hospitals across England.

In May 2022, Terumo, a medical technology company, announces that the UK's NHS England has selected the Spectra OptiaR Apheresis System through the NHS MedTech Funding Mandate to treat sickle cell disease. As a result, Spectra Optia will be deployed more widely in hospitals across England.

In January 2020, Fresenius Kabi unveiled Euro 30 million expansion of transfusion and apheresis disposables plant in Dominican Republic. The top government and company officials joined local executives and employees for the company's production site in the Dominican Republic.

Key Takeaways from the Apheresis Market Report Study

  • Market size analysis for current apheresis market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the apheresis market.
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
  • Key companies dominating the global apheresis market.
  • Various opportunities available for the other competitor in the apheresis market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current apheresis market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for apheresis market growth in the coming future?

Target Audience who can be benefited from this Apheresis Market Report Study

  • Apheresis products providers
  • Research organizations and consulting companies
  • Apheresis-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in apheresis machines and disposables
  • Various end users who want to know more about the apheresis market and latest technological developments in the apheresis market.

Frequently Asked Questions for Apheresis Market:

1. What is apheresis?

Apheresis is a medical technology used to separate various constituents of the blood, in which the remaining components of the blood are returned to the patient after extraction of the desired component (viz. erythrocytes, leukocytes, plasma, platelets etc.).

2. What is the market for the global Apheresis?

The global apheresis market was valued at USD 2,230.66 million in 2022 and is estimated to grow at a CAGR of 8.75% during the forecast period (2022-2028) to reach USD 3,671.55 million by 2030.

3. What are the drivers for the global Apheresis market?

The apheresis market is slated to witness prosperity owing to factors such as the increasing prevalence of hematological disorders such as sickle cell, anemia, blood cancers among others, the rise in the requirement of source plasma by various biopharmaceutical companies and an increase in the launch and approval of apheresis systems during the forecast period (2024-2030).

4. Who are the key players operating in the global Apheresis market?

Some of the key market players operating in the Apheresis market include Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter International, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V & Co., KG, Haier Inc., Otsuka Holdings and others.

5. Which region has the highest share in the Apheresis market?

North America is expected to dominate the overall apheresis market during the forecast period, 2024 to 2030. This can be ascribed to the rising prevalence of chronic diseases and cancers in the region. Moreover, the increase in the number of complex surgical procedures and the rising demand for blood components will also aid in the growth of the apheresis market in the North America region.

Table of Contents

1.Apheresis Market Report Introduction

2.Apheresis Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Apheresis Market Key Factors Analysis

  • 4.1. Apheresis Market Drivers
    • 4.1.1. Increasing prevalence of hematological disorders
    • 4.1.2. Rising demand of source plasma from biopharmaceutical companies.
    • 4.1.3. Favorable reimbursement policies and funding associated with apheresis procedures
  • 4.2. Apheresis Market Restraints and Challenges
    • 4.2.1. High cost involved in apheresis treatment
    • 4.2.2. Risks associated with the apheresis treatment
  • 4.3. Apheresis Market Opportunities
    • 4.3.1. Surge in innovation and R&D for new apheresis treatment methods, specially designed for children
    • 4.3.2. Reduction in the cost of lipoprotein apheresis and widespread availability of the therapy.

5. Apheresis Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Apheresis Market

7. Apheresis Market Layout

  • 7.1. By Product Type
    • 7.1.1. Apheresis machines
    • 7.1.2. Disposables
  • 7.2. By Technology
    • 7.2.1. Centrifugation
    • 7.2.2. Membrane filtration
  • 7.3. By Procedure
    • 7.3.1. Leukapheresis
    • 7.3.2. Plasmapheresis
    • 7.3.3. Plateletpheresis
    • 7.3.4. Erythrocytapheresis
    • 7.3.5. Others
  • 7.4. By Application
    • 7.4.1. Renal Disorders
    • 7.4.2. Hematological Disorders
    • 7.4.3. Neurological Disorders
    • 7.4.4. Autoimmune Disorders
    • 7.4.5. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Apheresis Market in USD million (2021-2030)
      • 7.5.1.2. Canada Apheresis Market in USD million (2021-2030)
      • 7.5.1.3. Mexico Apheresis Market in USD million (2021-2030)
    • 7.5.2. Europe
      • 7.5.2.1. France Apheresis Market in USD million (2021-2030)
      • 7.5.2.2. Germany Apheresis Market in USD million (2021-2030)
      • 7.5.2.3. United Kingdom Apheresis Market in USD million (2021-2030)
      • 7.5.2.4. Italy Apheresis Market in USD million (2021-2030)
      • 7.5.2.5. Spain Apheresis Market in USD million (2021-2030)
      • 7.5.2.6. Rest of Europe Apheresis Market in USD million (2021-2030)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Apheresis Market in USD million (2021-2030)
      • 7.5.3.2. Japan Apheresis Market in USD million (2021-2030)
      • 7.5.3.3. India Apheresis Market in USD million (2021-2030)
      • 7.5.3.4. Australia Apheresis Market in USD million (2021-2030)
      • 7.5.3.5. South Korea Apheresis Market in USD million (2021-2030)
      • 7.5.3.6. Rest of Asia Pacific Apheresis Market in USD million (2021-2030)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Apheresis Market in USD million (2021-2030)
      • 7.5.4.2. Africa Apheresis Market in USD million (2021-2030)
      • 7.5.4.3. South America Apheresis Market in USD million (2021-2030)

8. Apheresis Market Global Company Share Analysis - Key 3-5 Companies

9. Apheresis Market Company and Product Profiles

  • 9.1. Braun Melsungen AG
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. Asahi Kasei Corporation
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. Fresenius Kabi AG
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. Haemonetics Corporation
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. Terumo Corporation
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. Baxter International
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Kaneka Corporation
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Sumitomo Bakelite Company Limited
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Medica SPA
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Nikkiso Co., Ltd.
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. Cerus Corporation
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. Miltenyi Biotec B.V. & Co. KG
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Haier Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. Otsuka Holdings
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Apheresis Market
  • Table 3: Apheresis Market in Global (2021-2030)
  • Table 4: Apheresis Market in Global by Product Type (2021-2030)
  • Table 5: Apheresis Market in Global by Technology (2021-2030)
  • Table 6: Apheresis Market in Global by Procedure (2021-2030)
  • Table 7: Apheresis Market in Global by Application (2021-2030)
  • Table 8: Apheresis Market in Global by Geography (2021-2030)
  • Table 9: Apheresis Market in North America (2021-2030)
  • Table 10: Apheresis Market in North America by Country (2021-2030)
  • Table 11: Apheresis Market in the US (2021-2030)
  • Table 12: Apheresis Market in Canada (2021-2030)
  • Table 13: Apheresis Market in Mexico (2021-2030)
  • Table 14: Apheresis Market in Europe (2021-2030)
  • Table 15: Apheresis Market in Europe by Country (2021-2030)
  • Table 16: Apheresis Market in France (2021-2030)
  • Table 17: Apheresis Market in Germany (2021-2030)
  • Table 18: Apheresis Market in the United Kingdom (2021-2030)
  • Table 19: Apheresis Market in Italy (2021-2030)
  • Table 20: Apheresis Market in Spain (2021-2030)
  • Table 21: Apheresis Market in Rest of Europe (2021-2030)
  • Table 22: Apheresis Market in APAC (2021-2030)
  • Table 23: Apheresis Market in APAC by Country (2021-2030)
  • Table 24: Apheresis Market in China (2021-2030)
  • Table 25: Apheresis Market in Japan (2021-2030)
  • Table 26: Apheresis Market in India (2021-2030)
  • Table 27: Apheresis Market in Australia (2021-2030)
  • Table 28: Apheresis Market in South Korea (2021-2030)
  • Table 29: Apheresis Market in Rest of APAC (2021-2030)
  • Table 30: Apheresis Market in Rest of World (2021-2030)
  • Table 31: Apheresis Market in RoW by Region (2021-2030)
  • Table 32: Apheresis Market in Middle East (2021-2030)
  • Table 33: Apheresis Market in Africa (2021-2030)
  • Table 34: Apheresis Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Apheresis Market
  • Figure 3: Apheresis Market in Global (2021-2030)
  • Figure 4: Apheresis Market in Global by Product Type (2021-2030)
  • Figure 5: Apheresis Market in Global by Technology (2021-2030)
  • Figure 6: Apheresis Market in Global by Procedure (2021-2030)
  • Figure 7: Apheresis Market in Global by Application (2021-2030)
  • Figure 8: Apheresis Market in Global by Geography (2021-2030)
  • Figure 9: Apheresis Market in North America (2021-2030)
  • Figure 10: Apheresis Market in North America by Country (2021-2030)
  • Figure 11: Apheresis Market in the US (2021-2030)
  • Figure 12: Apheresis Market in Canada (2021-2030)
  • Figure 13: Apheresis Market in Mexico (2021-2030)
  • Figure 14: Apheresis Market in Europe (2021-2030)
  • Figure 15: Apheresis Market in Europe by Country (2021-2030)
  • Figure 16: Apheresis Market in France (2021-2030)
  • Figure 17: Apheresis Market in Germany (2021-2030)
  • Figure 18: Apheresis Market in the United Kingdom (2021-2030)
  • Figure 19: Apheresis Market in Italy (2021-2030)
  • Figure 20: Apheresis Market in Spain (2021-2030)
  • Figure 21: Apheresis Market in Rest of Europe (2021-2030)
  • Figure 22: Apheresis Market in APAC (2021-2030)
  • Figure 23: Apheresis Market in APAC by Country (2021-2030)
  • Figure 24: Apheresis Market in China (2021-2030)
  • Figure 25: Apheresis Market in Japan (2021-2030)
  • Figure 26: Apheresis Market in India (2021-2030)
  • Figure 27: Apheresis Market in Australia (2021-2030)
  • Figure 28: Apheresis Market in South Korea (2021-2030)
  • Figure 29: Apheresis Market in Rest of APAC (2021-2030)
  • Figure 30: Apheresis Market in Rest of World (2021-2030)
  • Figure 31: Apheresis Market in RoW by Region (2021-2030)
  • Figure 32: Apheresis Market in Middle East (2021-2030)
  • Figure 33: Apheresis Market in Africa (2021-2030)
  • Figure 34: Apheresis Market in South America (2021-2030)
  • Figure 35: Market Drivers
  • Figure 36: Market Barriers
  • Figure 37: Marker Opportunities
  • Figure 38: PORTER'S Five Force Analysis